Adolescent and young adult patients with acute lymphoblastic leukaemia have been shown to benefit from paediatric inspired treatment regimens, however these regimens present unique challenges when it comes to adverse-event management. Today we’ve invited Dr Patrick Brown, Director of the Paediatric Leukaemia Programme at Johns Hopkins Medicine, Baltimore, to discuss how to reduce the risk of adverse events in these settings.

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

References:

- Silverman LB, et al. Blood. 2001; 97(5):1211-8.

- Verma A, et al. Pediatr Hematol Oncol. 2019; 36(5):277-286.

- Baruchel A, et al. ESMO Open 2020;5:e000977

- Cooper SL, et al. Pediatr Blood Cancer. 2019; 66(8):e27797.

- Verma A, et al. Blood. 2018; 132(Suppl 1):5205

- Marini BL, et al. Leuk Lymphoma. 2019; 60(12):2854-2868.

This independent educational activity is supported by educational grants from Servier Pharmaceuticals LLC and Takeda. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Servier and Takeda have had no influence on the content of this education.